These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma? van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861 [TBL] [Abstract][Full Text] [Related]
28. Marginal zone lymphoma involving subcutaneous fat: appearance by FDG-PET/CT, MRI, and contrast-enhanced CT imaging. Chong EA; Torigian DA; Mato AR; Downs LH; Schuster SJ Clin Nucl Med; 2008 Oct; 33(10):692-3. PubMed ID: 18806570 [No Abstract] [Full Text] [Related]
29. Impact of FDG-PET/CT in the management of lymphoma. Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934 [TBL] [Abstract][Full Text] [Related]
30. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476 [TBL] [Abstract][Full Text] [Related]
31. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. Tirumani SH; LaCasce AS; Jacene HA PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087 [TBL] [Abstract][Full Text] [Related]
32. From PET/CT to PET/MRI: advances in instrumentation and clinical applications. Hu Z; Yang W; Liu H; Wang K; Bao C; Song T; Wang J; Tian J Mol Pharm; 2014 Nov; 11(11):3798-809. PubMed ID: 25058336 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic imaging and image-guided interventions of hepatobiliary malignancies. Udayasankar U; Chamsuddin A; Mittal P; Small WC Cancer Treat Res; 2008; 143():199-228. PubMed ID: 18619219 [No Abstract] [Full Text] [Related]
34. [Imaging examinations in lymphoma]. Terauchi T Nihon Rinsho; 2014 Mar; 72(3):430-5. PubMed ID: 24724398 [TBL] [Abstract][Full Text] [Related]
35. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement. Morimoto T; Tateishi U; Maeda T; Arai Y; Nakajima Y; Edmund Kim E Eur J Radiol; 2008 Sep; 67(3):508-13. PubMed ID: 17904324 [TBL] [Abstract][Full Text] [Related]
36. Recent advances in imaging of pancreatic neoplasms. Rabinowitz CB; Prabhakar HB; Sahani DV Cancer Treat Res; 2008; 143():229-54. PubMed ID: 18619220 [No Abstract] [Full Text] [Related]
37. Recent advances in imaging of male reproductive tract malignancies. Fütterer JJ; Spermon JR Cancer Treat Res; 2008; 143():331-64. PubMed ID: 18619225 [No Abstract] [Full Text] [Related]
38. The added value of PET/Ce-CT/DW-MRI fusion in assessment of hepatic focal lesions: PET/Ce-CT/DW-MRI fusion in hepatic focal lesion. Salem S; Houseni M; Zidan L; Kandil A Nucl Med Biol; 2015 Jul; 42(7):637-42. PubMed ID: 25907467 [TBL] [Abstract][Full Text] [Related]
39. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096 [TBL] [Abstract][Full Text] [Related]
40. Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Koh DM; Hughes M; Husband JE Abdom Imaging; 2006; 31(6):632-43. PubMed ID: 16897278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]